New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
10:00 EDTHEK, RDC, LUV, LSTR, FTI, PH, TKC, MKSI, KKR, CELG, VTR, MGM, SPN, MFC, JOY, DOVOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Celgene (CELG) upgraded to Outperform from Sector Perform at RBC Capital... Celgene (CELG) upgraded to Overweight from Neutral at Piper Jaffray... Dover (DOV) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Buy from Neutral at Sterne Agee... Joy Global (JOY) upgraded to Overweight from Neutral at Piper Jaffray... KKR & Co. (KKR) upgraded to Buy from Neutral at Goldman... Landstar System (LSTR) upgraded to Outperform from Market Perform at Wells Fargo... MKS Instruments (MKSI) upgraded to Buy from Neutral at BofA/Merrill... Manulife Financial (MFC) upgraded to Buy from Neutral at BofA/Merrill... Southwest (LUV) upgraded to Buy from Hold at Deutsche Bank... Superior Energy (SPN) upgraded to Outperform from Sector Perform at RBC Capital... Turkcell (TKC) upgraded to Overweight from Neutral at HSBC... Rowan Companies (RDC) upgraded to Neutral from Underweight at JPMorgan... MGM Resorts (MGM) upgraded to Outperform from Neutral at Credit Suisse... Parker-Hannifin (PH)upgraded to Overweight from Neutral at JPMorgan... Ventas (VTR) upgraded to Buy from Hold at Jefferies... Heckmann (HEK) upgraded to Neutral from Sell at Ladenburg.
News For DOV;CELG;FTI;JOY;KKR;LSTR;MFC;MKSI;LUV;SPN;TKC;RDC;MGM;PH;HEK;VTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
07:34 EDTCELGCelgene presents long-term OTEZLA data at ACR/ARHP meeting
Celgene announced that results from long-term efficacy and safety analyses of OTEZLA from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in Boston. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4, approved by the U.S. FDA for the treatment of adult patients with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In PALACE 1, 84 percent of patients who completed one year of 30 mg twice daily therapy continued to receive OTEZLA at two years. Improvements in efficacy measures observed at 52 weeks were sustained through 104 weeks of treatment. At week 104, among patients receiving OTEZLA 30 mg twice daily, the ACR20 response rate was 65.3 percent. ACR50 and 70 response rates were 34.0 percent and 19.6 percent, respectively, at week 104. Similar findings were observed in PALACE 4. In this trial, nearly 84 percent of DMARD-naïve patients who completed one year of OTEZLA 30 mg twice daily monotherapy continued to receive OTEZLA at two years. At week 104, among patients treated with OTEZLA 30 mg twice daily monotherapy, an ACR20, 50 and 70 response was reached by 61.4 percent, 40.7 percent and 19.2 percent of patients, respectively. In both PALACE 1 and PALACE 4, changes in other efficacy measures—including the HAQ-DI, which assesses improvements in physical function, and swollen and tender joint counts—were also generally sustained between weeks 52 and 104 with continued OTEZLA treatment. In PALACE 4, treatment with OTEZLA in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in improvements in enthesitis and dactylitis that were sustained through 104 weeks of treatment.
07:29 EDTMGMDeutsche Bank to hold a conference
Subscribe for More Information
06:17 EDTSPNSuperior Energy initiated with a Buy at SunTrust
Subscribe for More Information
November 17, 2014
07:16 EDTCELGMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
17:13 EDTMGMAppaloosa gives quarterly update on stakes
NEW STAKES: NXP Semiconductors (NXPI), Lorillard (LO), Alibaba (BABA), and Shire (SHPG). INCREASED STAKES: Whirlpool (WHR), Priceline (PCLN), Delta (DAL), CBS (CBS), and General Motors (GM). DECREASED STAKES: American Airlines (AAL), Disney (DIS), Apple (AAPL), MGM Resorts (MGM), and Eastman Chemical (EMN). LIQUIDATED STAKES: Expedia (EXPE), AIG (AIG), Prudential (PRU), Celanese (CE), and ASML Holding (ASML).
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
16:58 EDTPHThird Point gives quarterly update on stakes
NEW STAKES: Alibaba (BABA), eBay (EBAY), Bed Bath & Beyond (BBBY), Shire (SHPG), and Parker Hannifin (PH). INCREASED STAKES: Actavis (ACT), Amgen (AMGN), EQT (EQT), Sensata (ST), Coca-Cola Enterprises (CCE). DECREASED STAKES: Williams Cos (WMB), Ally Financial (ALLY), Cheniere Energy (LNG), YPF (YPF), and FedEx (FDX). LIQUIDATED STAKES: AIG (AIG), T-Mobile (TMUS), Rackspace (RAX), Hertz (HTZ), and Citrix Systems (CTXS).
10:03 EDTDOVHigh option volume stocks
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:31 EDTMFCManulife sees using cash for growth, acquisitions, dividends, Reuters reports
Manulife Financial says share buyouts are not "high" on its priority list, but says other possible uses for its cash include internal growth, acquisitions and dividends, Reuters reports. Reference Link
November 13, 2014
15:45 EDTRDCHalliburton, Baker Hughes in fast-moving merger talks, WSJ reports
Subscribe for More Information
14:05 EDTMGMNew Jersey reports Atlantic City gaming win down 4.4% to $207.23M
Subscribe for More Information
10:01 EDTJOYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:56 EDTMGMMacau to ask for eased restrictions on RMB conversion, Macau Business Daily says
Subscribe for More Information
05:57 EDTMFCManulife Financial reports Q3 EPS C$0.57 vs. C$0.54 last year
Subscribe for More Information
November 12, 2014
16:03 EDTJOYJoy Global initiated with a Hold at Brean Capital
Subscribe for More Information
15:29 EDTMFCNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Wal-Mart (WMT), consensus $1.12; Viacom (VIAB), consensus $1.68; Tyco (TYC), consensus 56c; Kohl's (KSS), consensus 74c; Helmerich & Payne (HP), consensus $1.67; Sally Beauty (SBH), consensus 40c; Manulife Financial (MFC), consensus 40c; TransDigm (TDG), consensus $2.02; MAXIMUS (MMS), consensus 52c.
12:17 EDTDOVDover management to meet with Stifel
Meeting to be held in San Francisco on November 13 hosted by Stifel.
07:59 EDTRDC, FTIMitsubishi UFJ to hold a tour
Subscribe for More Information
05:55 EDTKKRKKR, CITIC Limited jointly invest in United Envirotech
CITIC Limited and KKR jointly announce the formation of a consortium through related entities, CITIC Environment Protection Co. Ltd. and KKR China Water Investment Holdings Limited respectively, to make a pre-conditional voluntary offer, or VGO, for all the shares in United Envirotech, or UEL. The transaction allows CITIC to become the controlling shareholder of UEL through the holding of a majority interest in the consortium. This will be achieved by the consortium through the VGO subject to conditions being met, to acquire existing shares in UEL from the existing shareholders including KKR. In addition, after the VGO, the consortium will subscribe for further shares in UEL by way of a private placement totalling SGD50M, SGD100M or SGD150M which will provide additional capital to UEL. The offer price values UEL at approximately SGD1.9B on fully diluted basis. The consortium intends to maintain the listing status of UEL post transaction.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use